Skip to main content

Table 3 Adverse events

From: A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers

Toxicity

G1

G2

G3

G4

Total

Allergic rhinitis

2

1

0

0

3

Alopecia

2

0

0

0

2

ALT 1

1

0

1

0

2

Anorexia

2

4

0

0

6

AST 2

1

0

0

0

1

Bilirubin

1

0

0

0

1

Cardiac ischemia

0

0

1

0

1

Chest tightness

1

0

0

0

1

Constipation

4

4

0

0

8

Dehydration

0

0

1

0

1

Diarrhea

5

2

1

0

8

Distension

0

0

1

0

1

Dizziness

2

0

0

0

2

Dry mouth

1

0

0

0

1

Dry skin

1

0

0

0

1

Dysphagia

1

0

0

0

1

Dyspnea

2

2

6

0

10

Edema

12

1

0

0

13

Fatigue

5

3

5

0

13

Fever (no neutropenia)

1

0

0

0

1

Flushing

1

0

0

0

1

Hand-foot syndrome

1

0

0

0

1

Hemoglobin

1

2

0

0

3

Hypocalcemia

1

0

0

0

1

Hypokalemia

2

0

2

0

4

Hypomagnesemia

1

0

0

0

1

Insomnia

2

5

1

0

8

Mood alteration

0

1

0

0

1

Mucositis

4

0

0

0

4

Nausea

4

6

1

0

11

Neuropathy (sensory)

3

2

0

0

5

Neutrophils

0

2

1

0

3

Ocular surface disease

1

1

1

0

3

Ocular/visual

2

0

0

0

2

Pain

12

6

1

0

19

Palpitations

1

0

0

0

1

Platelets

1

0

0

0

1

Pleural effusion

1

0

0

0

1

Pruritis

1

0

0

0

1

Rash

6

0

0

0

6

Rigors/chills

2

0

0

0

2

Sinus tachycardia

1

0

0

0

1

Somnolence

3

0

0

0

3

Sweating

1

0

0

0

1

Taste alteration

5

4

0

0

9

Upper respiratory infection

1

0

0

0

1

Voice change

2

0

0

0

2

Vomiting

2

2

0

0

4

Watery eye

1

0

0

0

1

  1. Adverse events reported according to the Cancer Therapy Evaluation Program Common Toxicity Criteria, version 3.0. 1: ALT – alanine aminotransferase elevation; 2: AST – aspartate aminotransferase elevation.